Cargando…

Strategies for enhancing CAR T cell expansion and persistence in HIV infection

Chimeric Antigen Receptor (CAR) T cell therapies are tremendously successful in hematological malignancies and show great promise as treatment and curative strategy for HIV. A major determinant for effective CAR T cell therapy is the persistence of CAR T cells. Particularly, antigen density and targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothemejer, Frederik Holm, Lauritsen, Nanna Pi, Søgaard, Ole Schmeltz, Tolstrup, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475529/
https://www.ncbi.nlm.nih.gov/pubmed/37671164
http://dx.doi.org/10.3389/fimmu.2023.1253395
_version_ 1785100736960397312
author Rothemejer, Frederik Holm
Lauritsen, Nanna Pi
Søgaard, Ole Schmeltz
Tolstrup, Martin
author_facet Rothemejer, Frederik Holm
Lauritsen, Nanna Pi
Søgaard, Ole Schmeltz
Tolstrup, Martin
author_sort Rothemejer, Frederik Holm
collection PubMed
description Chimeric Antigen Receptor (CAR) T cell therapies are tremendously successful in hematological malignancies and show great promise as treatment and curative strategy for HIV. A major determinant for effective CAR T cell therapy is the persistence of CAR T cells. Particularly, antigen density and target cell abundance are crucial for the engagement, engraftment, and persistence of CAR T cells. The success of HIV-specific CAR T cells is challenged by limited antigen due to low cell surface expression of viral proteins and the scarcity of chronically infected cells during antiretroviral therapy. Several strategies have been explored to increase the efficacy of CAR T cells by enhancing expansion and persistence of the engineered cells. This review highlights the challenges of designing CAR T cells against HIV and other chronic viral infections. We also discuss potential strategies to enhance CAR T cell expansion and persistence in the setting of low antigen exposure.
format Online
Article
Text
id pubmed-10475529
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104755292023-09-05 Strategies for enhancing CAR T cell expansion and persistence in HIV infection Rothemejer, Frederik Holm Lauritsen, Nanna Pi Søgaard, Ole Schmeltz Tolstrup, Martin Front Immunol Immunology Chimeric Antigen Receptor (CAR) T cell therapies are tremendously successful in hematological malignancies and show great promise as treatment and curative strategy for HIV. A major determinant for effective CAR T cell therapy is the persistence of CAR T cells. Particularly, antigen density and target cell abundance are crucial for the engagement, engraftment, and persistence of CAR T cells. The success of HIV-specific CAR T cells is challenged by limited antigen due to low cell surface expression of viral proteins and the scarcity of chronically infected cells during antiretroviral therapy. Several strategies have been explored to increase the efficacy of CAR T cells by enhancing expansion and persistence of the engineered cells. This review highlights the challenges of designing CAR T cells against HIV and other chronic viral infections. We also discuss potential strategies to enhance CAR T cell expansion and persistence in the setting of low antigen exposure. Frontiers Media S.A. 2023-08-21 /pmc/articles/PMC10475529/ /pubmed/37671164 http://dx.doi.org/10.3389/fimmu.2023.1253395 Text en Copyright © 2023 Rothemejer, Lauritsen, Søgaard and Tolstrup https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Rothemejer, Frederik Holm
Lauritsen, Nanna Pi
Søgaard, Ole Schmeltz
Tolstrup, Martin
Strategies for enhancing CAR T cell expansion and persistence in HIV infection
title Strategies for enhancing CAR T cell expansion and persistence in HIV infection
title_full Strategies for enhancing CAR T cell expansion and persistence in HIV infection
title_fullStr Strategies for enhancing CAR T cell expansion and persistence in HIV infection
title_full_unstemmed Strategies for enhancing CAR T cell expansion and persistence in HIV infection
title_short Strategies for enhancing CAR T cell expansion and persistence in HIV infection
title_sort strategies for enhancing car t cell expansion and persistence in hiv infection
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475529/
https://www.ncbi.nlm.nih.gov/pubmed/37671164
http://dx.doi.org/10.3389/fimmu.2023.1253395
work_keys_str_mv AT rothemejerfrederikholm strategiesforenhancingcartcellexpansionandpersistenceinhivinfection
AT lauritsennannapi strategiesforenhancingcartcellexpansionandpersistenceinhivinfection
AT søgaardoleschmeltz strategiesforenhancingcartcellexpansionandpersistenceinhivinfection
AT tolstrupmartin strategiesforenhancingcartcellexpansionandpersistenceinhivinfection